Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20060866 | 0.87 | GPR119 (0.44) | HCRTR1HCRTR2HRH3GPR119FFAR1 | |
| SCHEMBL20061083 | 0.85 | NR1H2 (0.48) | HCRTR1HCRTR2HRH3GPR119HTR1A | |
| SCHEMBL20061081 | 0.85 | NR1H2 (0.48) | HCRTR1HCRTR2HRH3GPR119HTR1A | |
| SCHEMBL30451268 | 0.85 | NR1H2 (0.48) | HCRTR1HCRTR2HRH3GPR119HTR1A | |
| SCHEMBL20060926 | 0.82 | NR1H2 (0.39) | HCRTR1HCRTR2HRH3GPR119FFAR1 | |
| SCHEMBL20068607 | 0.81 | ABHD6 (0.40) | P2RX7NR1H2NR1H3SLC6A9 | |
| SCHEMBL20068552 | 0.80 | HRH3 (0.41) | HRH3GPR119 | |
| SCHEMBL20068692 | 0.80 | GPR119 (0.49) | HRH3GPR119NR1H2NR1H3 | |
| SCHEMBL20077739 | 0.80 | NR1H2 (0.38) | GPR119FFAR1NR1H2NR1H3OPRK1 | |
| SCHEMBL20061020 | 0.80 | NR1H2 (0.47) | HCRTR1HCRTR2HRH3GPR119HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2018071317-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | HCRTR1 359/4885HCRTR2 366/4885HRH3 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.